Jacqueline Vuky

4.5k total citations · 3 hit papers
64 papers, 2.6k citations indexed

About

Jacqueline Vuky is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jacqueline Vuky has authored 64 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 33 papers in Surgery and 31 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jacqueline Vuky's work include Bladder and Urothelial Cancer Treatments (26 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Urinary and Genital Oncology Studies (15 papers). Jacqueline Vuky is often cited by papers focused on Bladder and Urothelial Cancer Treatments (26 papers), Cancer Immunotherapy and Biomarkers (22 papers) and Urinary and Genital Oncology Studies (15 papers). Jacqueline Vuky collaborates with scholars based in United States, Spain and Netherlands. Jacqueline Vuky's co-authors include Dean F. Bajorin, Elizabeth R. Plimack, Petros Grivas, Arjun Vasant Balar, Ronald de Wit, Joaquim Bellmunt, Peter H. O’Donnell, Daniel Castellano, Noah M. Hahn and Mary J. Savage and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Cancer.

In The Last Decade

Jacqueline Vuky

56 papers receiving 2.5k citations

Hit Papers

First-line pembrolizumab in cisplatin-ineligible patients... 2017 2026 2020 2023 2017 2022 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    2017 939 citations Arjun Vasant Balar, Daniel Castellano et al. The Lancet Oncology profile →
  2. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
    2022 144 citations Jacqueline Vuky et al. profile →
  3. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
    2022 125 citations Jacqueline Vuky, Elisabeth I. Heath et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jacqueline Vuky United States 25 1.4k 1.4k 681 565 289 64 2.6k
Lisa Sengeløv Denmark 19 1.4k 1.0× 2.1k 1.5× 1.1k 1.6× 581 1.0× 303 1.0× 45 3.5k
Andreas H. Marx Germany 26 1.3k 0.9× 583 0.4× 822 1.2× 698 1.2× 177 0.6× 75 2.2k
D. Fennelly Ireland 25 1.8k 1.2× 878 0.6× 564 0.8× 417 0.7× 112 0.4× 85 2.6k
Bradley A. McGregor United States 27 1.8k 1.2× 1.2k 0.8× 1.4k 2.1× 782 1.4× 270 0.9× 176 3.2k
Giuseppe Badalamenti Italy 25 1.0k 0.7× 441 0.3× 764 1.1× 621 1.1× 182 0.6× 144 2.3k
Thomas Powles United Kingdom 24 2.4k 1.7× 1.9k 1.4× 1.1k 1.6× 649 1.1× 558 1.9× 105 3.7k
María Alsina Spain 22 1.3k 0.9× 803 0.6× 1.3k 1.9× 595 1.1× 177 0.6× 109 2.5k
Hakan Alakus Germany 29 763 0.5× 900 0.6× 925 1.4× 743 1.3× 255 0.9× 113 2.3k
Yuji Sakuma Japan 26 589 0.4× 474 0.3× 1.2k 1.8× 698 1.2× 136 0.5× 90 2.3k
Atsuo Takashima Japan 30 1.7k 1.1× 923 0.7× 1.5k 2.2× 388 0.7× 161 0.6× 222 2.9k

Countries citing papers authored by Jacqueline Vuky

Since Specialization
Citations

This map shows the geographic impact of Jacqueline Vuky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jacqueline Vuky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jacqueline Vuky more than expected).

Fields of papers citing papers by Jacqueline Vuky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jacqueline Vuky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jacqueline Vuky. The network helps show where Jacqueline Vuky may publish in the future.

Co-authorship network of co-authors of Jacqueline Vuky

This figure shows the co-authorship network connecting the top 25 collaborators of Jacqueline Vuky. A scholar is included among the top collaborators of Jacqueline Vuky based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jacqueline Vuky. Jacqueline Vuky is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aggarwal, Rahul, Jacqueline Vuky, David James VanderWeele, et al.. (2025). Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 43(15). 1824–1834. 5 indexed citations
2.
Chatta, Gurkamal, Christos E. Kyriakopoulos, Nicholas Iannotti, et al.. (2023). 1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results. Annals of Oncology. 34. S982–S983. 4 indexed citations
3.
4.
Balar, Arjun Vasant, Daniel Castellano, Petros Grivas, et al.. (2022). Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals of Oncology. 34(3). 289–299. 65 indexed citations
5.
Feng, Zizhen & Jacqueline Vuky. (2021). Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook. PubMed. 35(3507). 410–420. 6 indexed citations
6.
Aggarwal, Rahul, Jacqueline Vuky, David James VanderWeele, et al.. (2021). 591P A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 32. S639–S639. 1 indexed citations
7.
Grivas, Petros, Arjun Vasant Balar, Jacqueline Vuky, et al.. (2020). 744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC). Annals of Oncology. 31. S577–S578. 2 indexed citations
8.
Grivas, Petros, Elizabeth R. Plimack, Arjun Vasant Balar, et al.. (2020). Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. European Urology Oncology. 3(3). 351–359. 33 indexed citations
9.
Balar, Arjun Vasant, Daniel Castellano, Peter H. O’Donnell, et al.. (2017). First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. The Lancet Oncology. 18(11). 1483–1492. 939 indexed citations breakdown →
10.
Balar, Arjun Vasant, Joaquim Bellmunt, Peter H. O’Donnell, et al.. (2016). Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study. Annals of Oncology. 27. vi567–vi567. 49 indexed citations
11.
12.
Vitolins, Mara Z., Leah Griffin, Jacqueline Vuky, et al.. (2013). Randomized Trial to Assess the Impact of Venlafaxine and Soy Protein on Hot Flashes and Quality of Life in Men With Prostate Cancer. Journal of Clinical Oncology. 31(32). 4092–4098. 32 indexed citations
13.
Jones, Robert J., Jacqueline Vuky, Tony Elliott, et al.. (2013). Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer. Investigational New Drugs. 31(4). 1001–1007. 34 indexed citations
14.
Vuky, Jacqueline, Huong Pham, Erika J. Douglass, et al.. (2011). Phase II Study of Long-Term Androgen Suppression With Bevacizumab and Intensity-Modulated Radiation Therapy (IMRT) in High-Risk Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics. 82(4). e609–e615. 18 indexed citations
15.
McGonigle, Kathryn F., Howard G. Muntz, Jacqueline Vuky, et al.. (2011). Combined weekly topotecan and biweekly bevacizumab in women with platinum‐resistant ovarian, peritoneal, or fallopian tube cancer. Cancer. 117(16). 3731–3740. 56 indexed citations
16.
Pruthi, Sandhya, Rui Qin, Heshan Liu, et al.. (2011). A phase III, randomized, placebo-controlled, double-blind trial of flaxseed for the treatment of hot flashes. Menopause The Journal of The North American Menopause Society. 19(1). 48–53. 53 indexed citations
17.
Vuky, Jacqueline, Christopher R. Porter, Christina Isacson, et al.. (2009). Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high‐risk, locally advanced prostate cancer. Cancer. 115(4). 784–791. 39 indexed citations
18.
Vuky, Jacqueline, Christina Isacson, Mehran Fotoohi, et al.. (2005). Phase II trial of imatinib (Gleevec®) in patients with metastatic renal cell carcinoma. Investigational New Drugs. 24(1). 85–88. 33 indexed citations
19.
Kondagunta, G. Varuni, Jennifer Bacik, Lawrence Schwartz, et al.. (2004). Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors. Investigational New Drugs. 22(2). 177–179. 9 indexed citations
20.
Vuky, Jacqueline, John McCaffrey, Michelle S. Ginsberg, et al.. (2000). Phase II Trial of Pyrazoloacridine in Patients with Cisplatin-Refractory Germ Cell Tumors. Investigational New Drugs. 18(3). 265–267. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa Sengeløv Breakdown of academic impact, for papers by Andreas H. Marx Breakdown of academic impact, for papers by D. Fennelly Breakdown of academic impact, for papers by Bradley A. McGregor Breakdown of academic impact, for papers by Giuseppe Badalamenti Breakdown of academic impact, for papers by Thomas Powles Breakdown of academic impact, for papers by María Alsina Breakdown of academic impact, for papers by Hakan Alakus Breakdown of academic impact, for papers by Yuji Sakuma Breakdown of academic impact, for papers by Atsuo Takashima
Rankless by CCL
2026